Skip to main content

Publication: two CE8 sub-studies

Publication: two CE8 sub-studies

CE8 radiotherapy quality assurance

Willmann J, Verhoeff JJC, Kaidar-Person O, Abrunhosa-Branquinho A, Clementel E, Corning C, Portik D, Souza L, Reijneveld JC, Dhermain F, Hurkmans C, Monti AF, Saez J, Mason WP, Weller M, Roth P, Andratschke N. Quality assurance in the randomized multicentre phase III trial EORTC-1709-BTG/CCTG CE.8 (MIRAGE) for glioblastoma: Results of the radiotherapy delineation benchmark case procedure. Radiotherapy and Oncology 211: 111088. 2025. https://doi.org/10.1016/j.radonc.2025.111088 
 
The multicentre randomised phase III trial EORTC-1709-BTG/CCTG CE.8 (MIRAGE) (NCT03345095) analysed the addition of the proteasome inhibitor marizomib to temozolomide-based chemoradiotherapy with 60 Gy in 30 fractions in patients with newly diagnosed glioblastoma. Researchers analysed the benchmark case procedure for delineation and planning radiotherapy quality assurance (RTQA) that was performed before patient inclusion.

CE8 as part of a proton pump inhibitor use meta-analysis
Le Rhun E, Sain D, Erridge SC, Reardon DA, Minniti G, Roth P, Wick W, Nabors B, Sampson J, Mason W, Cloughesy T, Reijneveld JC, Stupp R, Preusser M, Gorlia T, Weller M. Proton Pump Inhibitor Use and Survival in Patients With Newly Diagnosed Glioblastoma. JAMA Network Open 8: e2545578-e2545578. 2025. https://doi.org/10.1001/jamanetworkopen.2025.45578 
 

Reserarcher wanted to understand if exposure of patients with newly diagnosed glioblastoma to proton pump inhibitors associated with survival outcomes. This meta-analysis of individual data from 2981 patients enrolled into 5 prospective clinical trials found that the use of proton pump inhibitors that are potent activators of aldehyde dehydrogenase 1 A1 was associated with inferior survival outcomes, independently of MGMT promoter methylation status and steroid use.